1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 11 studies

Compound Research Comparison

Studies (1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine)	Trials (1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine)	Recent Studies (post-2010) (1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine)	Studies (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)	Trials (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)	Recent Studies (post-2010) (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
14	1	0	3,859	8	1,052

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	10 (90.91)	18.2507
2000's	1 (9.09)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akunne, HC; Cooke, LW; Davis, MD; DeMattos, SB; Georgic, LM; MacKenzie, RG; Rugsley, TA; Shih, YH; van Leeuwen, DH; Whetzel, SZ	1
Christoffersen, CL; Corbin, AE; Heffner, TG; Meltzer, LT; Ninteman, FW; Serpa, KA; Wiley, JN; Wise, LD	1
Feng, MR; Siersma, PR; Strenkoski, CA; Wright, DS	1
Caprathe, BW; Downing, DM; Glase, SA; Heffner, TG; Jaen, JC; Johnson, SJ; Kesten, SR; MacKenzie, RG; Meltzer, LT; Wright, JL	1
Downing, DM; Feng, MR; Hayes, RN; Heffner, TG; MacKenzie, RG; Meltzer, LT; Pugsley, TA; Wise, LD; Wright, JL	1
Christoffersen, CL; Corbin, AE; Feng, MR; Heffner, TG; Meltzer, LT; Ninteman, FW; Strenkoski, CA; Tucker, EV; Wang, Y; Wiley, JN; Wright, DS	1
Atherton, J; Feng, MR; Knoll, S; Strenkoski, CA; Wright, DS	1
Cutler, NR; Eldon, MA; Feng, MR; Hourani, J; Jhee, SS; Posvar, E; Sedman, AJ; Sramek, JJ	1
Feng, MR; Loo, J; Wright, J	1
Davis, MD; Giordani, AB; Iyer, RN; Juneau, PL	1
Bubl, B; Feuerstein, TJ; Hubbe, U; Huethe, F; Jackisch, R; Löffler, M; McIntosh, JM	1

Trials

1 trial(s) available for 1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Article	Year
Initial safety, tolerability pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia. Psychopharmacology bulletin, 1998, Volume: 34, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adolescent; Adult; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia	1998

Other Studies

10 other study(ies) available for 1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Article	Year
CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects. The Journal of pharmacology and experimental therapeutics, 1995, Volume: 274, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 4-Butyrolactone; Acetylcholine; Adenylyl Cyclases; Animals; Antipsychotic Agents; Autoreceptors; CHO Cells; Cricetinae; Dihydroxyphenylalanine; Dopamine; Dopamine Agonists; Guinea Pigs; Male; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Serotonin	1995
CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects. The Journal of pharmacology and experimental therapeutics, 1995, Volume: 274, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Apomorphine; Autoreceptors; Avoidance Learning; Basal Ganglia Diseases; Dopamine Agonists; Male; Mice; Motor Activity; Rats; Rats, Sprague-Dawley; Saimiri	1995
Sensitive high-performance liquid chromatographic method for a dopamine receptor agonist, CI-1007, and its metabolite PD 147693 in monkey plasma. Journal of chromatography. B, Biomedical applications, 1995, Mar-10, Volume: 665, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Dopamine Agonists; Haplorhini; Reproducibility of Results; Spectrometry, Fluorescence	1995
The discovery and structure-activity relationships of 1,2,3,6-tetrahydro-4-phenyl-1-[(arylcyclohexenyl)alkyl]pyridines. Dopamine autoreceptor agonists and potential antipsychotic agents. Journal of medicinal chemistry, 1994, Oct-14, Volume: 37, Issue:21 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antipsychotic Agents; Avoidance Learning; Brain; CHO Cells; Cricetinae; Crystallography, X-Ray; Cyclic AMP; Cyclohexanes; Cyclohexenes; Dopamine; Dopamine Agonists; Mice; Models, Molecular; Molecular Structure; Motor Activity; Pyridines; Rats; Receptors, Dopamine; Saimiri; Stereoisomerism; Structure-Activity Relationship; Substantia Nigra	1994
Identification, characterization and pharmacological profile of three metabolites of (R)-(+)-1,2,3,6-tetrahydro-4-phenyl-1-[(3-phenylcyclohexen-1- yl)methyl]pyridine (CI-1007), a dopamine autoreceptor agonist and potential antipsychotic agent. Journal of medicinal chemistry, 1995, Dec-22, Volume: 38, Issue:26 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Autoreceptors; Avoidance Learning; Brain; CHO Cells; Chromatography, High Pressure Liquid; Cricetinae; Dopamine; Dopamine Agonists; Humans; Hydroxylation; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Motor Activity; Rats; Receptors, Dopamine; Saimiri	1995
Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. Pharmaceutical research, 1997, Volume: 14, Issue:3 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antipsychotic Agents; Avoidance Learning; Dopamine; Male; Motor Activity; Neural Inhibition; Neurons; Rats; Rats, Sprague-Dawley; Rats, Wistar; Saimiri	1997
Determination of two CI-1007 sulfate metabolites in monkey plasma and urine. Journal of chromatography. B, Biomedical sciences and applications, 1997, May-23, Volume: 693, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Benzenesulfonates; Chromatography, High Pressure Liquid; Drug Stability; Haplorhini; Pyridines; Sensitivity and Specificity; Spectrometry, Fluorescence	1997
Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling. Drug metabolism and disposition: the biological fate of chemicals, 1998, Volume: 26, Issue:10 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Dogs; Humans; Macaca fascicularis; Male; Rats; Rats, Wistar; Species Specificity	1998
Brain extracellular levels of the putative antipsychotic CI-1007 and its effects on striatal and nucleus accumbens dopamine overflow in the awake rat. The Journal of pharmacy and pharmacology, 1998, Volume: 50, Issue:10 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Blood-Brain Barrier; Brain; Chromatography; Dopamine; Dopamine Agonists; Male; Mass Spectrometry; Microdialysis; Nucleus Accumbens; Rats; Rats, Sprague-Dawley; Visual Cortex	1998
Dopamine release in human neocortical slices: characterization of inhibitory autoreceptors and of nicotinic acetylcholine receptor-evoked release. Brain research bulletin, 2006, Jan-30, Volume: 68, Issue:5 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adolescent; Adult; Aged; Alkaloids; Analysis of Variance; Animals; Autoreceptors; Azocines; Calcium; Child; Child, Preschool; Domperidone; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Feedback; Female; Fluvoxamine; Humans; In Vitro Techniques; Isoxazoles; Male; Maprotiline; Mice; Middle Aged; Neocortex; Nicotine; Nicotinic Antagonists; Potassium; Pyrrolidines; Quinolizines; Rats; Receptors, Nicotinic; Sulpiride; Time Factors; Tritium	2006